

PERSONAL INFORMATION **Alessandra Carobbio**SCIENTIFIC PROFILE  
SUMMARY

Master's degree in Biostatistics, active in the field of scientific research for over 15 years, documented by 112 indexed publications for a total H-index of 53 (source: Google Scholar). National scientific qualification as associate professor for concurrency area 06/M1 (GSD 24: 06-MEDS-24) obtained in April 2021.

Currently associate professor of medical statistics at the Department of Medical and Surgical, Maternal, Infant and Adult Sciences, University of Modena-Reggio Emilia. Extensive knowledge of clinical trial regulatory regulations gained from three years' experience as a member of two independent Ethics Committees.

Several collaborations with hospital health management for the development of strategic corporate projects.

Undergraduate teaching in several Graduate Courses, in Italian and English.

Responsibility for data analysis and coordination of Italian, European and international multicenter studies according to GCP standards.

Experience as a biostatistician on staff at the Phase I Unit and member of the CTQC.

Main area of application in oncohematology, but experience in research collaborations in multiple areas: pediatric, neurological, surgical-transplant, infectious disease, cardiology, internist.

Application and development of advanced statistical analysis methods.

Main software of use: STATA, R, SAS

## WORK EXPERIENCE

2023 - now

**Associate Professor of Medical Statistic**

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO-EMILIA

Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell'Adulto

2013 – 2023

**Senior biostatistician**

FROM - ONDAZIONE PER LA RICERCA OSPEDALE DI BERGAMO ETS

ASST "PAPA GIOVANNI XXIII" – Piazza OMS,1 – 24127 Bergamo

2010 – 2013

**Expert in Biostatistics at Ethics Committee (EC) according to the Ministerial Decree of 12/05/2006, in staff to the Scientific Secretariat.**

1. ETHIC COMMITTEE - AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" and ASST "PAPA GIOVANNI XXIII" Bergamo
2. ETHIC COMMITTEE - OSPEDALI SAN GIUSEPPE DI MILANO E SACRA FAMIGLIA DI ERBA (C.E.MI.ER)

2007 – 2010

**FIRC - Fondazione Italiana per la Ricerca sul Cancro-AIRC Fellowship**

Three-year Cancer Research Fellowship for the project "The use of C-statistics for assessing prognostic value of new biomarkers in the risk stratification of patients with myeloproliferative disorders"

AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" – Unit of Hematology.

## EDUCATION AND TRAINING

2021-2032

**NATIONAL SCIENTIFIC QUALIFICATION AS ASSOCIATE PROFESSOR (GSD 24: 06-MEDS-24: MEDICAL STATISTIC)**

- Habilitated 26.04.2021

2003 - 2006

**BIostatistica e Statistica Sperimentale (class: 92 / S)**

Università degli Studi di Milano Bicocca – Facoltà di Scienze Statistiche

▪ Master degree, 110 e lode / 110. Defense date: 21/04/2006

2000 - 2003

**SCIENZE STATISTICHE, DEMOGRAFICHE E SOCIALI (class: 37)**

Università degli Studi di Milano Bicocca – Facoltà di Scienze Statistiche

▪ Bachelor degree, 110 e lode / 110. Defense date: 7/11/2003

TEACHING ACTIVITIES

UNIVERSITY LECTURING

a.y. 2010/11 (16 hours)

a.y. 2011/12 (16 hours)

a.y. 2022/23 (16 hours)

**Module title “Statistica medica” of the course “Igiene, medicina del lavoro e statistica medica”**

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - FACOLTÀ DI MEDICINA E CHIRURGIA

Corso di Laurea in Infermieristica

Corso di Laurea in Ostetricia

a.y. 2010/11 (10 hours)

a.y. 2011/12 (10 hours)

a.y. 2012/13 (10 hours)

a.y. 2013/14 (10 hours)

a.y. 2014/15 (10 hours)

a.y. 2015/16 (10 hours)

**Module title “Elementi di Statistica, metodi, strumenti indicatori”**

UNIVERSITÀ DEGLI STUDI DI BERGAMO - COLLEGIO IPASVI BERGAMO

Master universitario di I livello “Management per le funzioni di coordinamento per le professioni sanitarie infermieristiche e ostetriche”

a.y. 2019/20 (10 hours)

a.y. 2020/21 (10 hours)

a.y. 2021/22 (10 hours)

a.y. 2022/23 (10 hours)

**Module title “Applications of medical statistics” of the elective course “Turning clinical experience into research projects”**

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - SCHOOL OF MEDICINE AND SURGERY

a.y. 2021/22 (4 hours)

a.y. 2022/23 (4 hours)

a.y. 2023/24 (4 hours)

a.y. 2024/25 (4 hours)

**Module title “Statistical distribution functions”**

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - SCHOOL OF MEDICINE AND SURGERY

Master universitario di II livello “MEDAL (Methods and Data Analysis) in Biomedical Research”

a.y. 2022/23 (8 hours)

a.y. 2023/24 (6 hours)

**Module title “Health technology assessment”**

UNIVERSITÀ DEGLI STUDI DI BERGAMO

Corso di Laurea in Ingegneria per le Tecnologie della Salute

a.y. 2023/24 (6 hours)

**Module title “Medical statistics”**

UNIVERSITÀ DEGLI STUDI DI BERGAMO

Master Universitario di II livello “INTERNATIONAL MASTER OF CARDIOLOGY AND TECHNIQUES APPLIED TO CARDIAC SURGERY”

a.y. 2023/24 (30 hours)

**Module title “Statistica medica”**

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Scuola di specializzazione in Farmacologia Clinica

2024 edition (14 hours)

**Module title “Regressione lineare semplice e multipla”**

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di perfezionamento “Statistica applicata ai quesiti clinici”

RESEARCH PROJECTS
 

---

01/01/2012 - 31/12/2017

 Biostatistic of the **International Working Group for MPN Research and Treatment (IWG-MRT)** working on these project:

1. **Review of WHO diagnostic criteria for polycythemia vera and prefibrotic myelofibrosis** (Swerdlow SH, et al. *WHO classification of Tumours of Haematopoietic and Lymphoid Tissues*. 4th edn. Lyon, France: International Agency for Research on Cancer; 2017)
2. **Implementation and validation of a new thrombotic risk score (IPSET-thrombosis) in essential thrombocythemia**, included in the guideline: *NCCN Guidelines for Patients Myeloproliferative Neoplasms, Version: 2.2021*

01/01/2013 - 15/12/2023

Biostatistician involved in the statistical analysis of the following international collaborative projects:

1. CVT-MPN study (*Cerebral Vein Thrombosis in Myeloproliferative Neoplasms Study*)
2. AVK-DOACs MPN survey (*Survey of venous thrombosis of patients with Ph-negative Myeloproliferative Neoplasms*)
3. PRISM study (*Preventing Recurrent Ischemic Stroke in Myeloproliferative neoplasms study*)
4. RT-pre-PMF study (*Risk of Thrombosis in prefibrotic Primary Myelofibrosis*)
5. MPN-K study (*Secondary Cancers in Myeloproliferative Neoplasms study*)
6. MPN-DOACs study (*Use of Direct Oral Anticoagulants (DOACs) in patients with Ph-negative Myeloproliferative Neoplasms study*)
7. *Ph-negative Myeloproliferative Neoplasms study*)
8. MPN-COVID study (*Myeloproliferative neoplasms (MPN) and COVID-19 study*)
9. ERNEST 2.0 study (*European Registry for Myeloproliferative Neoplasms (MPNs)- Update of ERNEST study*)
10. ROPEG-PV study (*Observational study on the use of ropeginterferon alfa-2b in polycythemia vera*)

01/01/2014 - 31/12/2015

 Member of the Methodology Committee of "**CUBE guidelines for hematology**" sponsored by **Società Italiana di Ematologia (SIE)**

01/01/2017 - 15/12/2023

 Leading biostatistician and Steering Committee member of the **RCT Fase II study "The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (Low-PV)"** (ClinicalTrials.gov identifier: NCT03003325)

15/01/2020 – 15/12/2023

 Participation in the European project **HARMONY** (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology) - Bid Data Platform for the collection and harmonization of data from clinical trials in the field of hematology

15/12/2019 - 15/12/2023

Statistician at the Phase I Unit of ASST Papa Giovanni XXIII in Bergamo according to Determina AIFA n. 809/2015

06/02/2023 - 15/12/2023

 Member of the **Clinical Trial Quality Team (CTQT)** at the **Phase I Unit** of ASST Papa Giovanni XXIII in Bergamo according to Determina AIFA n. 809/2015

 PUBLIC HEALTH PROJECTS
 

---

21/12/2010 - 31/12/2013

 Member of the **Gruppo Operativo Intensità di Cure (GOIC)**, established by the Management of the AO "Ospedali Riuniti di Bergamo" by resolution No.0052716/2010 to comply with the need to have a permanent reference group at the corporate level with functions of study, design, implementation and monitoring of an organization based on intensity of care..

01/01/2019 - 31/12/2021

Collaborator in the **ALFRED** (*Automatic process pLanning support software For InteRnal hospital and Ethic comitee Documental organizzation*) project, an IT platform to support the management and tracking of clinical trials submitted for approval by the EC and the economic feasibility study according to the new European Clinical Trials Regulation No. 536/2014.

## HONORS AND AWARDS

---

- 2007 **Winner of “Premio per la Statistica Medica e l’Epidemiologia Clinica”**  
**Società Italiana di Statistica Medica ed Epidemiologia Clinica, SISMEC**
- Call for application for the 5 best undergraduate, doctoral, postgraduate and master theses on topics in statistical and epidemiological methodology applied to clinical and public health problems.
- 2014 **Winner of “Premio Guido Berlucci Giovani Ricercatori”**  
**Fondazione Guido Berlucci**
- Call for applications for Italian researchers under the age of 40 who have published relevant research in the field of oncology in journals indexed 1st or 2nd name.
- 2016 **Winner of “Fellowship Program – Area oncoematologica”**  
**GILEAD**
- Call for proposals designed to support the design and implementation of projects of a scientific or social-health nature aimed at furthering public health goals and improving disease outcomes and quality of life for patients with HIV, hepatitis C, oncohematological diseases, and invasive fungal infections.

## PEER REVIEWER FOR MEDICAL AND SCIENTIFIC JOURNALS

---

- 2020 – now
- **Annals of Hematology** - Springer Nature (ISSN: 0939-5555)
- 2021 – now
- **Blood Advances** (ISSN: 2473-9537)
  - **Blood Cancer Journal** (ISSN: 2044-5385)
- 2022 – now
- **Haematologica** (ISSN: 0390-6078)
  - **Future Oncology** (ISSN: 1479-6694)
  - **Thrombosis Research** (ISSN: 1879-2472)
- 2023 - now
- **Blood** (ISSN: 0006-4971)
  - **Nature Medicine** (ISSN: 1078-8956)
  - **Transfusion and Apheresis Science** (ISSN: 1473-0502)

## POSTER/ORAL/WORKSHOP COMMUNICATIONS WITHIN CONGRESSES

---

Participation in several meetings of scientific societies (ASH, EHA, ELN, SISMEC, AFI) , with oral and poster presentations. The following oral presentations are noted:

- 10/12/2007 Oral presentation of the abstract “**Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia**” at the 49th **American Society of Hematology (ASH)** Meeting in Atlanta, USA
- 11/11/2019 Speaker of the presentation “**Improving the grading system of the risk of thrombosis in PV**” at the International Meeting Consensus statement by the **European LeukemiaNet (ELN)** on “Unmet clinical needs of management of thrombosis in Myeloproliferative Neoplasms,” sponsored by the Menarini Foundation
- 20/09/2024 Oral presentation of the abstract “**The role of polypharmacy in people living with HIV**” at the **Società Italiana di Statistica medica e Epidemiologia clinica (SISMEC)** congress in Modena, Italy

## PUBLICATION

---

- Author and co-author of **112 scientific publications** in international peer-reviewed journals (see annex). **H-index: 53; i10-index: 94** (source: Google Scholar). Last updated: 01/07/2025

## ANNEXES

---

- Comprehensive list of publications (updated July 1, 2025).

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 – GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018.

## Publication list [112 publications up to 01/07/2025]

**1. Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.**

Barbui T, Stefano V, Rossi E, Ghirardi A, **Carobbio A**, Loscocco GG, Condorelli A, Guglielmelli P. *Am J Hematol.* 2025 Mar 10. doi: 10.1002/ajh.27657. Online ahead of print. PMID: 40062566.

**2. Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.**

Guglielmelli P, Ghirardi A, **Carobbio A**, Masciulli A, Morrone L, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Boldrini V, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larrán A, Andreasson B, Vannucchi AM, Barbui T. *Hemasphere.* 2025 Jan 31;9(2):e70072. doi: 10.1002/hem3.70072. PMID: 39897086.

**3. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis.**

Barbui T, **Carobbio A**, Ghirardi A, Fenili F, Finazzi MC, Castelli M, Vannucchi AM, Guglielmelli P, Rambaldi A, Gangat N, Tefferi A. *Blood Cancer J.* 2024 Nov 6;14(1):195. doi: 10.1038/s41408-024-01176-7. PMID: 39505848.

**4. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.**

Barbui T, Ghirardi A, **Carobbio A**, De Stefano V, Rambaldi A, Tefferi A, Vannucchi AM. *Blood Cancer J.* 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6. PMID: 39455571.

**5. Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropoginterferon alfa-2b therapy.**

Barbui T, **Carobbio A**, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, De Stefano V, Ramundo F, Finazzi MC, Rambaldi A, Vannucchi AM. *Br J Haematol.* 2024 Dec;205(6):2287-2294. doi: 10.1111/bjh.19813. PMID: 39375955

**6. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.**

Ghirardi A, **Carobbio A**, Guglielmelli P, Rambaldi A, De Stefano V, Vannucchi AM, Tefferi A, Barbui T. *Blood Cancer J.* 2024 Apr 22;14(1):68. doi: 10.1038/s41408-024-01052-4. PMID: 38649342

**7. Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients.**

Barbui T, **Carobbio A**. *Blood Cancer J.* 2024 Jan 23;14(1):17. doi: 10.1038/s41408-024-00987-y. PMID: 38253717

**8. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.**

Barbui T, **Carobbio A**, Thiele J, Gangat N, Rumi E, Rambaldi A, Vannucchi AM, Tefferi A; IWG-MRT group. *Blood Cancer J.* 2023 Dec 15;13(1):187. doi: 10.1038/s41408-023-00960-1. PMID: 38102114

**9. Ropoginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.**

Barbui T, **Carobbio A**, De Stefano V, Alvarez-Larrán A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. *Ann Hematol.* 2023 Dec 7. doi: 10.1007/s00277-023-05577-9. Online ahead of print. PMID: 38060001

**10. Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?**

Barbui T, **Carobbio A**, Vannucchi AM, De Stefano V. *Blood Adv.* 2023 Dec 26;7(24):7551-7553. doi: 10.1182/bloodadvances.2023012007. PMID: 37874911

**11. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.**

Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardani A, Hanson CA, Ketterling RP, De Stefano V, **Carobbio A**, Barbui T, Guglielmelli P, Gangat N, Vannucchi AM. *Am J Hematol.* 2023 Dec;98(12):1829-1837. doi: 10.1002/ajh.27079. PMID: 37665758

**12. Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support.**

Colombo J, Gattoni C, **Carobbio A**, Nacoti M, Pelliccioli I, Vedovati S, Bonanomi E. *Minerva Pediatr (Torino).* 2023 Oct;75(5):689-696. doi: 10.23736/S0026-4946.20.05574-7. PMID: 32493000

**13. Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.**

Cuomo M, **Carobbio A**, Aloisi M, Alvisi P, Banzato C, Bosa L, Bramuzzo M, Campanozzi A, Catassi G, D'Antiga L, Di Paola M, Felici E, Fioretti MT, Gatti S, Graziano F, Lega S, Lionetti P, Marseglia A, Martinelli M, Musto F, Sansotta N, Scarallo L, Zuin G, Norsa L.

*Inflamm Bowel Dis.* 2023 Sep 1;29(9):1380-1389. doi: 10.1093/ibd/izac215. PMID: 36222487

**14. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer**

Barbui T, Gavazzi A, Sciatti E, Finazzi MC, Ghirardi A, Carioli G, **Carobbio A**.

*Curr Hematol Malig Rep.* 2023 Aug;18(4):105-112. doi: 10.1007/s11899-023-00697-5. PMID: 37221411

**15. Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.**

**Carobbio A**, Vannucchi AM, Rumi E, De Stefano V, Rambaldi A, Carli G, Randi ML, Gisslinger H, Passamonti F, Thiele J, Gangat N, Tefferi A, Barbui T.

*Blood Cancer J.* 2023 Jul 28;13(1):115. doi: 10.1038/s41408-023-00887-7. PMID: 37507408

**16. Ropoginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera**

Barbui T, Vannucchi AM, De Stefano V, **Carobbio A**, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.

*NEJM Evid.* 2023 Jun;2(6):EVIDoA2200335. doi: 10.1056/EVIDoA2200335. PMID: 38320126

**17. One-year mortality in COVID-19 is associated with patients' comorbidities rather than pneumonia severity.**

Novelli L, Raimondi F, Carioli G, **Carobbio A**, Pappacena S, Biza R, Trapasso R, Anelli M, Amoroso M, Allegri C, Malandrino L, Imeri G, Conti C, Beretta M, Gori M, D'Elia E, Senni M, Lorini FL, Rizzi M, Cosentini R, Rambaldi A, Masciulli A, Gavazzi A, Solidoro P, Sironi S, Fagioli S, Barbui T, Marco FD; HPG23 Covid19 Study Group.

*Respir Med Res.* 2023 Jun;83:100976. doi: 10.1016/j.resmer.2022.100976. PMID: 36473331

**18. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.**

Barbui T, Ghirardi A, **Carobbio A**, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM.

*Blood Cancer J.* 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. PMID: 36385103

**19. Breakthrough infections in MPN-COVID vaccinated patients.**

Barbui T, **Carobbio A**, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Grieshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nalęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM.

*Blood Cancer J.* 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921

**20. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.**

Barbui T, **Carobbio A**, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Grieshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM.

*Am J Hematol.* 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27. PMID: 36111658

**21. Adherence of ticagrelor in real world patients with aCute coronary syndrome: The AD-HOC study.**

Fiocca L, Rossini R, Carioli G, **Carobbio A**, Piazza I, Collaku E, Giubilato S, Amico F, Molfese M, De Benedictis M, Calabria P, Limbruno U, Valente S, Ferlini M, Spezzano T, Senni M, Gavazzi A.

*Int J Cardiol Heart Vasc.* 2022 Jul 18;42:101092. doi: 10.1016/j.ijcha.2022.101092. eCollection 2022 Oct. PMID: 35873861

**22. Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children.**

Nacoti M, **Carobbio A**, Finazzi S, Pelliccioli I, Consonni F, Ferrari F, Favarato M, Fazzi F, Bonanomi E.

*Minerva Anesthesiol.* 2022 Nov;88(11):890-900. doi: 10.23736/S0375-9393.22.16293-0. Epub 2022 Jul 14. PMID: 35833854

**23. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.**

Barbui T, Carobbio A, De Stefano V.

*Res Pract Thromb Haemost.* 2022 Feb 7;6(1):e12657. doi: 10.1002/rth2.12657. PMID: 35155976

**24. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.**

Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, Ramundo F, Rossi E, Kanthi Y, Tefferi A, Barbui T.

*Blood Cancer J.* 2022 Feb 10;12(2):28. doi: 10.1038/s41408-022-00625-5. PMID: 35145055

**25. Second versus first wave of COVID-19 in patients with MPN.**

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nalęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM.

*Leukemia.* 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. PMID: 35064223

**26. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria.**

Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, Carobbio A, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagioli S.

*Cancers (Basel).* 2021 Nov 27;13(23):5976. doi: 10.3390/cancers13235976. PMID: 34885087

**27. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.**

Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larran A, Andreasson B, Vannucchi AM, Barbui T.

*Blood Adv.* 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. PMID: 34753179

**28. Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19.**

Gori M, Ghirardi A, D'Elia E, Imeri G, Di Marco F, Gavazzi A, Carobbio A, Balestrieri G, Giammarresi A, Trevisan R, Amoroso M, Raimondi F, Novelli L, Magro B, Mangia G, Lorini FL, Fagioli S, Barbui T, Rizzi M, Cosentini R, Sironi S, Senni M.

*Eur J Prev Cardiol.* 2022 May 5;29(5):e196-e199. doi: 10.1093/eurjpc/zwab143. PMID: 34535993

**29. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases.**

Gangat N, Guglielmelli P, Betti S, Farrukh F, Carobbio A, Barbui T, Vannucchi AM, De Stefano V, Tefferi A.

*Am J Hematol.* 2021 Dec 1;96(12):1580-1586. doi: 10.1002/ajh.26336. PMID: 34453762

**30. Long-term follow-up of recovered MPN patients with COVID-19.**

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A.

*Blood Cancer J.* 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. PMID: 34135309

**31. The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives.**

Ferrari F, Nacoti M, Carobbio A, Favarato M, DI Dedda GB, Bonanomi E.

*Minerva Pediatr (Torino).* 2021 Jun 15. doi: 10.23736/S2724-5276.21.06133-4. Online ahead of print. PMID: 34128601

**32. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.**

Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marin F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J.

*Leukemia.* 2021 Oct;35(10):2989-2993. doi: 10.1038/s41375-021-01279-1. PMID: 34012132

**33. Response to: Ruxolitinib withdrawal due to the COVID-19.**

Barbui T, Carobbio A.

*Leukemia.* 2021 Apr;35(4):1219. doi: 10.1038/s41375-021-01187-4. PMID: 33633312

**34. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.**

Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM.

*Blood Cancer J.* 2021 Feb 4;11(2):21. doi: 10.1038/s41408-021-00417-3. PMID: 33563901

**35. Ropoginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.**

Barbui T, Vannucchi AM, De Stefano V, Masciulli A, **Carobbio A**, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.

*Lancet Haematol.* 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571

**36. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.**

Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A.

*Leukemia.* 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. PMID: 33414483

**37. A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis.**

**Carobbio A**, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S, Rambaldi A, Finazzi MC, Thiele J, Vannucchi AM, Tefferi A, Barbui T.

*Blood Cancer J.* 2020 Oct 14;10(10):100. doi: 10.1038/s41408-020-00368-1. PMID: 33056979

**38. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.**

Guglielmelli P, **Carobbio A**, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T.

*Blood Cancer J.* 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2. PMID: 32098944

**39. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.**

Masciulli A, Ferrari A, **Carobbio A**, Ghirardi A, Barbui T.

*Blood Adv.* 2020 Jan 28;4(2):380-386. doi: 10.1182/bloodadvances.2019001158. PMID: 31985808

**40. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study**

De Stefano V, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson CIM, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

*Blood.* 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614. PMID: 3186940731869407

**41. Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study**

Pozzi A, Gori M, Iorio A, Iacovoni A, **Carobbio A**, Cioffi G, De Maria R, Grosu A, Fontana A, Canova PA, Calabrese A, Ferrari P, Parati G, Lorini FL, Senni M, Gavazzi A.

*Eur J Prev Cardiol.* 2020 Dec;27(19):2326-2329. doi: 10.1177/2047487319896431. PMID: 31847560

**42. Second cancers in MPN: Survival analysis from an international study.**

Marchetti M, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

*Am J Hematol.* 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. PMID: 31816122

**43. Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?**

Barbui T, **Carobbio A**, Ferrari A.

*Blood Adv.* 2019 Dec;3(23):3951-3952. doi: 10.1182/bloodadvances.2019001159. PMID: 31805188

**44. Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study).**

Brucato A, Ferrari A, Tiraboschi M, Zucchi A, Cogliati C, Torzillo D, Dentali F, Tavecchia L, Gessi V, Squizzato A, Moretti S, Permunian ET, **Carobbio A**, Pasina L, De Stefano F, Tombetti E, Cumetti D, Tognoni G, Barbui T.  
*Eur J Intern Med.* 2020 Feb;72:60-66. doi: 10.1016/j.ejim.2019.10.016. PMID: 31757579

**45. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.**

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, **Carobbio A**, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.  
*Am J Hematol.* 2020 Feb; 95(2):156-166. doi: 10.1002/ajh.25677.PMID: 31721282

**46. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.**

**Carobbio A**, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T.  
*Blood Adv.* 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211. Review. PMID: 31175128

**47. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.**

Barbui T, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiano E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.  
*Leukemia.* 2019 May;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. PMID: 31142846

**48. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.**

Ferrari A, **Carobbio A**, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T.  
*Haematologica.* 2019 May;104(12):2391-2399. doi: 10.3324/haematol.2019.221234. PMID: 31123026

**49. Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study.**

Gritti P, Zangari R, **Carobbio A**, Zucchi A, Lorini FL, Ferri F, Agostinis C, Lanterna LA, Brembilla C, Foresti C, Barbui T, Biroli F.  
*World Neurosurg.* 2019 Apr;128:e531-e540. doi: 10.1016/j.wneu.2019.04.190. PMID: 31048051

**50. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.**

De Stefano V, Rossi E, **Carobbio A**, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.  
*Blood Cancer J.* 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y. PMID: 30420642

**51. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.**

De Stefano V, **Carobbio A**, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiano E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Corsari B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.  
*Blood Cancer J.* 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9. PMID: 29535299

**52. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.**

Marchetti M, **Carobbio A**, Capitoni E, Barbui T.  
*Am J Hematol.* 2018 May;93(5):698-703. doi: 10.1002/ajh.25049. PMID: 29377227

**53. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.**

Ghirardi A, **Carobbio A**, Masciulli A, Barbui T.  
*Blood Cancer J.* 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available. PMID: 29335456

**54. Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.**

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, **Carobbio A**, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.  
*J Clin Pathol.* 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. PMID: 28824010

**55. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.**

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, **Carobbio A**, Ghirardi A, Tognoni G.

*Am J Hematol.* 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. PMID: 28699191

**56. Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device.**

Iacovoni A, Vittori C, Fontana A, **Carobbio A**, Fino C, D'Elia E, Terzi A, Senni M.  
*Int J Artif Organs.* 2017 Apr 18;0. doi: 10.5301/ijao.5000573. PMID: 28430303

**57. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials.**

Barbui T, **Carobbio A**, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.  
*Haematologica.* 2017 Mar 2. pii: haematol.2017.165126. doi: 10.3324/haematol.2017.165126. PMID: 28255021

**58. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.**

Lussana F, **Carobbio A**, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.  
*J Hematol Oncol.* 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z. PMID: 28228104

**59. Diagnostic impact of the 2016 revised who criteria for polycythemia vera.**

Barbui T, Thiele J, Gisslinger H, **Carobbio A**, Vannucchi AM, Tefferi A.  
*Am J Hematol.* 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. PMID: 28196400

**60. ACE inhibitors and cyto-reductive therapy in polycythemia vera.**

Barbui T, Masciulli A, Ghirardi A, **Carobbio A**.  
*Blood.* 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. PMID: 28028024

**61. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.**

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, **Carobbio A**, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A.  
*JAMA.* 2016 Nov 8;316(18):1906-1912. doi: 10.1001/jama.2016.15826. PMID: 27825009

**62. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.**

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, **Carobbio A**, Griesshammer M, Barbui T.  
*Blood Cancer J.* 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103. PMID: 27813534

**63. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.**

Barbui T, Vannucchi AM, **Carobbio A**, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.  
*Am J Hematol.* 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. PMID: 27737508

**64. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.**

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, **Carobbio A**, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.  
*Leukemia.* 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. PMID: 27113812

**65. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.**

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Falcone C, Tefferi A.  
*Blood Cancer J.* 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. PMID: 26617062

**66. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.**

Massi D, Brusa D, Merelli B, Falcone C, Xue G, **Carobbio A**, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M.  
*Ann Oncol.* 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255. PMID: 26037795

**67. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.**

Barbui T, Vannucchi AM, **Carobbio A**, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.  
*Am J Hematol.* 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. PMID: 25683038

**68. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.**

Finazzi MC, **Carobbio A**, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T. *Leukemia*. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. PMID: 25482134

**69. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinicomorphological diagnosis.**

Barbui T, Thiele J, **Carobbio A**, Vannucchi AM, Tefferi A. *Leukemia*. 2015 Apr;29(4):992-3. doi: 10.1038/leu.2014.328. PMID: 25425199

**70. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.**

Barbui T, **Carobbio A**, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A. *Blood*. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. PMID: 25377561

**71. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.**

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, **Carobbio A**, Urso C, Mandalà M. *Mod Pathol*. 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137. PMID: 25341653

**72. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.**

Finazzi G, **Carobbio A**, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T. *Blood*. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676. PMID: 25323688

**73. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.**

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, **Carobbio A**, Rulli E, Deaglio S, Mandalà M. *Ann Oncol*. 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452. PMID: 25223485

**74. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.**

Lussana F, **Carobbio A**, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T. *Br J Haematol*. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. PMID: 25130523

**75. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.**

Martinelli I, De Stefano V, **Carobbio A**, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortelezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T. *Am J Hematol*. 2014 Nov;89(11):E200-5. doi: 10.1002/ajh.23809. PMID: 25042466

**76. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.**

Barbui T, Thiele J, Kvasnicka HM, **Carobbio A**, Vannucchi AM, Tefferi A. *Leukemia*. 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. PMID: 24888272

**77. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI).**

Rizzi M, Ravasio V, **Carobbio A**, Mattucci I, Crapis M, Stellini R, Pasticci MB, Chinello P, Falcone M, Grossi P, Barbaro F, Pan A, Viale P, Durante-Mangoni E; Investigators of the Italian Study on Endocarditis. *BMC Infect Dis*. 2014 Apr 29;14:230. doi: 10.1186/1471-2334-14-230. PMID: 24779617

**78. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.**

Barbui T, Thiele J, **Carobbio A**, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A. *Am J Hematol*. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. PMID: 24535932

**79. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.**

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, **Carobbio A**, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N. *Haematologica*. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. PMID: 24389309

**80. Masked polycythemia vera diagnosed according to WHO and BCSH classification.**

Barbui T, Thiele J, **Carobbio A**, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

*Am J Hematol.* 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617. PMID: 24166817

**81. Masked polycythemia vera (mPV): results of an international study.**

Barbui T, Thiele J, Gisslinger H, Finazzi G, **Carobbio A**, Rumi E, Luigia Randi M, Betozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

*Am J Hematol.* 2014 Jan;89(1):52-4. doi: 10.1002/ajh.23585. PMID: 23996471

**82. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.**

Barbui T, **Carobbio A**, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, Rambaldi A, Vannucchi AM, Barosi G.

*Leukemia.* 2013 Oct;27(10):2084-6. doi: 10.1038/leu.2013.207. PMID: 23828261

**83. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.**

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, **Carobbio A**, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.

*Leukemia.* 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. PMID: 23739289

**84. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.**

Ruella M, Salmoiraghi S, Risso A, **Carobbio A**, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.

*Exp Hematol.* 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. PMID: 23542632

**85. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).**

Barbui T, Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A.

*Blood.* 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. PMID: 23033268

**86. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.**

Passamonti F, Thiele J, Girodon F, Rumi E, **Carobbio A**, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

*Blood.* 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. PMID: 22740446

**87. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.**

Barbui T, Thiele J, **Carobbio A**, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.

*Blood.* 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. PMID: 22700720

**88. Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing.**

Zambelli M, Andorno E, De Carlis L, Rossi G, Cillo U, De Feo T, **Carobbio A**, Giacomoni A, Bottino G, Colledan M.

*Am J Transplant.* 2012 Aug;12(8):2198-210. doi: 10.1111/j.1600-6143.2012.04071.x. PMID: 22578214

**89. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.**

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, **Carobbio A**, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

*Am J Hematol.* 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. PMID: 22573503

**90. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.**

Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, Benedetti F, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, **Carobbio A**, Sacchi N, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo, GITMO.

*Leukemia.* 2012 Aug;26(8):1779-85. doi: 10.1038/leu.2012.55. PMID: 22377898

**91. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.**

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, **Carobbio A**, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A.

*Blood.* 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. PMID: 22246040

**92. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.**

**Carobbio A**, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.  
*Am J Hematol.* 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. PMID: 22237692

**93. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.**

Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.  
*Leukemia.* 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. PMID: 21926959

**94. ASXL1 mutations in primary and secondary myelofibrosis.**

Ricci C, Spinelli O, Salmoiraghi S, Finazzi G, **Carobbio A**, Rambaldi A.  
*Br J Haematol.* 2012 Feb;156(3):404-7. doi: 10.1111/j.1365-2141.2011.08865.x. PMID: 21923651

**95. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.**

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, **Carobbio A**, Gianatti A, Gangat N, Hanson CA, Tefferi A.  
*J Clin Oncol.* 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. PMID: 21747083

**96. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.**

**Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T.  
*Blood.* 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. PMID: 21490340

**97. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.**

Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, **Carobbio A**, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A.  
*J Clin Oncol.* 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. PMID: 21189387

**98. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.**

Barbui T, **Carobbio A**, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators.  
*Haematologica.* 2011 Feb;96(2):315-8. doi: 10.3324/haematol.2010.031070. PMID: 21173097

**99. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.**

Rambaldi A, Dellacasa CM, Finazzi G, **Carobbio A**, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T.  
*Br J Haematol.* 2010 Aug;150(4):446-55. doi: 10.1111/j.1365-2141.2010.08266.x. PMID: 20560970

**100. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.**

**Carobbio A**, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, Rodeghiero F, Delaini F, Rambaldi A, Barbui T.  
*Blood.* 2010 Aug 19;116(7):1051-5. doi: 10.1182/blood-2010-03-272179. PMID: 20479281

**101. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.**

Antonioli E, **Carobbio A**, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi AM.  
*Haematologica.* 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. PMID: 20418246

**102. Thrombosis in primary myelofibrosis: incidence and risk factors.**

Barbui T, **Carobbio A**, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G.  
*Blood.* 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. PMID: 19965680

**103. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.**

Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, **Carobbio A**, Rambaldi A, Barbui T, Bassan R.

Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. PMID: 19735261

**104. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.**

**Carobbio A**, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T. *Exp Hematol.* 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. PMID: 19559071

**105. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?**

Barbui T, **Carobbio A**, Rambaldi A, Finazzi G. *Blood.* 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. PMID: 19372254

**106. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.**

**Carobbio A**, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T. *Blood.* 2008 Oct 15;112(8):3135-7. doi: 10.1182/blood-2008-04-153783. PMID: 18587010

**107. Leukocytosis and risk stratification assessment in essential thrombocythemia.**

**Carobbio A**, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T. *J Clin Oncol.* 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. PMID: 18443353

**108. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).**

Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, **Carobbio A**, Intronà M, Barbui T, Golay J, Rambaldi A. *Leukemia.* 2008 Apr;22(4):740-7. PMID: 18079739

**109. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.**

Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, **Carobbio A**, Micò C, Rambaldi A, Golay J, Intronà M. *Bone Marrow Transplant.* 2007 Oct;40(8):785-91. PMID: 17680021

**110. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.**

Finazzi G, Rambaldi A, Guerini V, **Carobbio A**, Barbui T. *Haematologica.* 2007 Jan;92(1):135-6. PMID: 17229651

**111. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.**

**Carobbio A**, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. *Blood.* 2007 Mar 15;109(6):2310-3. PMID: 17110452

**112. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.**

Corrao G, Botteri E, Bagnardi V, Zambon A, **Carobbio A**, Falcone C, Leoni O. *Pharmacoepidemiol Drug Saf.* 2005 Jan;14(1):31-40. PMID: 15390219

Modena, July 01, 2025

